Biosimilar breast cancer drug trial pulled before it started
Disease control
Terminated
This study was designed to test whether a biosimilar version of pertuzumab (EG1206A) works as well as the original drug (Perjeta) in people with HER2-positive, hormone receptor-negative early breast cancer. Participants would have received either the biosimilar or the original dr…
Phase: PHASE3 • Sponsor: EirGenix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC